- Home
- DFP vs XOMA Comparison
DFP vs XOMA Comparison
Compare DFP & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DFP | XOMA |
|---|---|---|
| Founded | 2013 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.3M | 457.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DFP | XOMA |
|---|---|---|
| Price | $21.26 | $32.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $69.50 |
| AVG Volume (30 Days) | ★ 56.2K | 53.6K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $47,106,000.00 |
| Revenue This Year | N/A | $88.91 |
| Revenue Next Year | N/A | $13.80 |
| P/E Ratio | ★ N/A | $39.11 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $15.45 | $18.35 |
| 52 Week High | $19.31 | $39.92 |
Technical Indicators
Market Signals| Indicator | DFP | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 42.97 |
| Support Level | $20.87 | $31.18 |
| Resistance Level | $21.78 | $32.78 |
| Average True Range (ATR) | 0.18 | 1.53 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 46.16 | 24.73 |
Price Performance
Historical ComparisonAbout DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.